Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

Journal article

Open access

Peer reviewed

Min Huang, M. Catherine Pietanza, Ayman Samkari, James Pellissier, Thomas Burke, Sheenu Chandwani, Fansen Kong and A. Simon Pickard

PharmacoEconomics, v 37(1), pp 105-116

01 Jan 2019

PMID: 30515719

Files and links (1)

url

https://doi.org/10.1007/s40273-018-0752-0View

Published, Version of Record (VoR) Open

Original

17 Record Views

17 citations in Scopus

Title: Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer
Creators: Min Huang - Merck & Co., Inc., Rahway, NJ, USA (United States)
M. Catherine Pietanza - Merck & Co., Inc., Rahway, NJ, USA (United States)
Ayman Samkari - Merck & Co., Inc., Rahway, NJ, USA (United States)
James Pellissier - Merck & Co., Inc., Rahway, NJ, USA (United States)
Thomas Burke - MSD (Mexico)
Sheenu Chandwani - Merck & Co., Inc., Rahway, NJ, USA (United States)
Fansen Kong - Merck & Co., Inc., Rahway, NJ, USA (United States)
A. Simon Pickard - Health Outcomes Solutions (United States)
Publication Details: PharmacoEconomics, v 37(1), pp 105-116
Publisher: Springer International Publishing
Grant note: ;
Resource Type: Journal article
Language: English
Academic Unit: Pediatrics
Web of Science ID: WOS:000456486400010
Scopus ID: 2-s2.0-85057966920
Other Identifier: 991021838141004721

This publication has contributed to the advancement of the following goals:

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas: Economics; Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy